Does Wegovy Cause Memory Loss or Affect Cognitive Function?

Is memory loss listed as a Wegovy side effect anywhere?

The short answer is no. The NHS patient guidance for semaglutide sets out the known side-effect profile in plain language: nausea, vomiting, diarrhoea, constipation, stomach discomfort, headache, fatigue and dizziness are the most commonly reported effects. Memory loss, cognitive impairment or confusion do not appear on that list, and they are absent from the Wegovy Summary of Product Characteristics held on the Electronic Medicines Compendium.

That does not mean every person on semaglutide sails through without any cognitive symptoms. Patient forums and reports to medicines regulators include accounts of brain fog and word-finding difficulties. Regulators take these reports seriously, which is why the MHRA Yellow Card system exists: collecting individual reports over time is how emerging patterns get spotted. But at this point, no regulatory body has identified memory loss as a causal effect of Wegovy, and it has not triggered a formal safety communication of the kind the MHRA issued for pancreatitis risk in January 2026.

If you want to read the current listed side effects in full, the Wegovy patient leaflet guide covers what the official UK prescribing information says about risk, which is worth reading before or during treatment.

Could something else during Wegovy treatment explain the brain fog?

This is where the picture becomes more nuanced. Several things that happen when people start a GLP-1 treatment are independently capable of affecting concentration and memory:

Calorie intake often drops sharply, particularly in the first few weeks. The brain runs on glucose; if overall food consumption falls faster than the body adapts, some people notice cognitive sluggishness. Similarly, nausea and disrupted appetite can reduce protein intake below what the brain and muscles need, which compounds fatigue. Dehydration is another factor: if nausea suppresses drinking as well as eating, mild dehydration sets in quickly, and even mild dehydration is well-documented to impair short-term memory and attention.

Sleep quality changes are also worth mentioning. Significant weight loss can alter sleep architecture, and some people go through a period of lighter sleep as their body composition shifts. Poor sleep reliably produces the kind of foggy, forgetful feeling that could reasonably be attributed to the medicine rather than to the sleep disruption itself.

None of this means cognitive symptoms should be dismissed or ignored. It means there are treatable, addressable contributors that are worth investigating before assuming Wegovy itself is the culprit. Checking your water intake over a single day is a practical first step: if it consistently falls below six to eight glasses, dehydration is a reasonable early suspect. Our guide to Wegovy's reported effects covers the wider side-effect context in more detail.

What does early research say about GLP-1 medicines and brain health?

The emerging science here is genuinely interesting. Several large observational studies have examined whether GLP-1 receptor agonists are associated with dementia risk in people with type 2 diabetes. Results have generally pointed in the opposite direction from harm: some studies suggest these medicines may be associated with a lower incidence of cognitive decline compared with other diabetes treatments. Research into Parkinson's disease risk and GLP-1 medicines is also active, with some promising preliminary data.

These studies are not proof that Wegovy protects memory; they are largely observational, conducted in people with diabetes rather than people using semaglutide solely for weight management, and they cannot yet establish cause and effect. The population using Wegovy for weight loss is different in important ways from the populations studied so far. That is why scientists are careful to describe this as an active research area rather than a settled question.

What the evidence does not support is the idea that semaglutide is damaging memory. If anything, the early signals lean the other way. The MHRA Yellow Card scheme remains the appropriate route for reporting any cognitive symptom you experience during treatment, because individual reports feed directly into ongoing safety monitoring.

When should you speak to a prescriber about cognitive symptoms on Wegovy?

Promptly, rather than waiting to see whether it resolves. If you notice meaningful changes in memory, concentration or mental clarity after starting Wegovy or after a dose increase, raise it at your next clinical review. Do not wait for a scheduled follow-up if the symptoms are affecting daily life. A prescriber can help distinguish between medicine-related effects, nutritional contributors and unrelated causes, and can adjust your treatment plan accordingly.

People on Wegovy who also take other medicines should specifically mention this to their prescriber. Oral medicines, including some that are known to affect cognition, can be absorbed differently when gastric emptying slows. That is a mechanism worth exploring with clinical support rather than guessing at independently. You can explore the relationship between Wegovy and memory effects further, or look into other reported effects of Wegovy that patients sometimes ask about.

At nume, a real prescriber reads every consultation the same day it is submitted. If you have concerns about cognitive symptoms or want to understand whether Wegovy is clinically suitable for you, speaking to our prescribers is a sensible starting point. There is no obligation, and the consultation is free.